Skip to main content

Table 4 Proteins specifically recognised by IgG from patients with the same phenotype and expressing unidentified ANAa

From: Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor β pathway in patients with systemic sclerosis

Subset of patients

Protein ID on gel

HEp-2 cell protein

SwissProt accession number

MW th/es

pHi th/es

Number of unique identified peptides#

Total ion score

Best ion score

Sequence coverage (%)

dcSSc/SRC

1100

Calreticulin precursor (T)

[SwissProt:CALR_HUMAN]

48/63

4.3/4.4

5/16

136

36

25

 

1420

Pre-mRNA splicing factor SPF27 (N)

[SwissProt:SPF27_HUMAN]

26/25

5.5/5.9

6/10

377

115

47

 

1636

Eukaryotic translation initiation factor 5A-1 (N)

[SwissProt:IF5A1_HUMAN]

17/16

5.1/5.7

3/3

163

101

33

 

2249

Eukaryotic translation initiation factor 5A-1 (T)

[SwissProt:IF5A1_HUMAN]

17/17

5.1/5.6

2/5

80

69

22

dcSSc/PAH

-

-

-

-

-

    

dcSSc/ILD

589

Probable ATP-dependent RNA helicase DDX17 (N)

[SwissProt:DDX17_HUMAN]

72/76

8.8/8.0

8/20

207

35

36

 

1101

Poly(rC)-binding protein 2 (N)

[SwissProt:PCBP2_HUMAN]

39/39

6.3/6.9

5/10

132

56

41

 

1151

Serine/threonine protein phosphatase PP1-α catalytic subunit (N)

[SwissProt:PP1A_HUMAN]

37/35

5.9/6.5

10/17

476

114

61

dcSSc*

1417

DNA-directed RNA polymerases I, II and III, subunit RPABC1 (N)

[SwissProt:RPAB1_HUMAN]

25/25

5.7/6.3

2/4

150

117

21

 

2163

Cofilin 1 (T)

[SwissProt:COF1_HUMAN]

19/19

8.2/9.5

3/7

134

72

54

lcSSc/DU

2317

Histone H2A type 1-J (T)

[SwissProt:H2A1J_HUMAN]

14/16

10.9/6.1

2/3

37

20

27

lcSSc/PAH

882

Telomeric repeat binding factor 2-interacting protein 1 (N)

[SwissProt:TE2IP_HUMAN]

44/52

4.6/4.9

9/15

286

71

48

 

1119

Heterogeneous nuclear ribonucleoprotein A/B (N)

[SwissProt:ROAA_HUMAN]

36/38

8.2/6.5

3/5

55

27

15

 

2079

Peroxiredoxin 2 (T)

[SwissProt:PRDX2_HUMAN]

22/23

5.7/6.0

5/7

143

40

26

lcSSc/ILD

901

78-kDa glucose-regulated protein precursor (T)

[SwissProt:GRP78_HUMAN]

72/76

5.1/5.4

13/29

711

121

28

 

2063

ATP-dependent DNA helicase 2, subunit 1 (N)

[SwissProt:KU70_HUMAN]

70/70

6.2/6.9

3/14

89

45

29

lcSSc*

820

U4/U6 small nuclear ribonucleoprotein Prp31 (N)

[SwissProt:PRP31_HUMAN]

55/57

5.6/6.4

3/7

112

64

16

 

1478

Calumenin precursor (T)

[SwissProt:CALU_HUMAN]

37/44

4.5/4.6

3/7

82

39

29

 

1895

Tumour protein D54 (T)

[SwissProt:TPD54_HUMAN]

22/29

5.3/5.6

1/3

47

47

23

  1. aANA: antinuclear antibody; dcSSc: diffuse cutaneous systemic sclerosis; DU: digital ulcer; ILD: interstitial lung disease; lcSSc: limited cutaneous systemic sclerosis; MW: molecular weight (in kilodaltons); N: proteins recognised in HEp-2 cell-enriched nuclear protein extract; PAH: pulmonary arterial hypertension; SRC: scleroderma renal crisis; SSc: systemic sclerosis; T: proteins recognised in HEp-2 cell total protein extract; th/es: theoretical/estimated. bNumber of unique identified peptides in MS/MS and in MS+MS/MS searches. cWithout visceral involvement.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us